News

CRISPRMED24 Recordings Selection A - The First CRISPR Medicine Conference in Copenhagen, April 23-25, 2025

This selection includes presentations by: Keynote speaker: Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy (TIGET)), Karina Thorn (Novo Nordisk), Anna Cereseto (University of Trento), Karim Benabdellah El Khlanji (GENyO. Pfizer-University of Granada), Toni Cathomen (University of Freiburg), Seung Wook Yang (Amgen) and Jan Nelis (Ariya Bio).
Chairs: Alessia Cavazza (University College London) and Marcello Maresca (AstraZeneca)

- Jul. 20, 2024
News
CRISPRMED24 Recordings Selection A
  • Keynote Speaker: Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy (TIGET)) - Precision Genetic Engineering of Hematopoiesis by Gene Editing Tools
  • Karina Thorn (Novo Nordisk) - Transforming Gene Therapy From the Few to the Many
  • Anna Cereseto (University of Trento) - Identification and Evolution of Novel CRISPR-Cas9 Systems From the Human Microbiome
  • Karim Benabdellah El Khlanji (GENyO. Pfizer-University of Granada) - Connecting Innovators: CA21113 2nd Year Journey in Fostering Collaborative Networks for Breakthroughs in Genome Editing to Treat Human Diseases (GenE-Humdi COST action)
  • Toni Cathomen (University of Freiburg) - New Insights Into On- And Off-Target Effects of Genome Editing Tools
  • Seung Wook Yang (Amgen) - CRISPR-Based Functional Genomic Characterization of Mechanisms of Action of Degraders for Targeted Protein Degradation
  • Jan Nelis (Ariya Bio) - Project Delta Force - Upregulating delta globin as a new avenue to treat hemoglobinopathies

Chairs: Alessia Cavazza (University College London) and Marcello Maresca (AstraZeneca) |Access the recordings below with a CMN+ subscription.

Tags

HashtagCRISPRMED24HashtagCRISPRMED24 Recording

News: CRISPRMED24 Recordings Selection A - The First CRISPR Medicine Conference in Copenhagen, April 23-25, 2025
CLINICAL TRIALS
Solid Tumors, (NCT06598371)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Hereditary Angioedema, HAE, (NCT06634420)
Sponsors:
Intellia Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine